Biocon posts Rs 31 crore net profit in Q1FY26- Grow Mudra

Biocon posts Rs 31 crore net profit in Q1FY26

08 Aug , 2025 By : Debdeep Gupta

Biocon net profit before exceptional items rose 342% year-on-year to Rs 31 crore on a like-for-like basis for the first quarter of FY26, driven by robust growth in its biosimilars business and improved operating leverage across segments.

The company had a one-time benefit of Rs 1,057 crore in Q1 last year due to divestment of its India branded formulation units.

Operating revenue grew 15% YoY to Rs 3,942 crore, with EBITDA rising 19% to Rs 829 crore. Core EBITDA stood at Rs 1,003 crore, with margins at 25%.

The company spent Rs 205 crore net R&D or 7% of revenue, ex-Syngene.

“Our biosimilars and CRDMO businesses continued to deliver strong momentum, while generics held steady,” said Kiran Mazumdar-Shaw, Chairperson of Biocon Group. “The recent QIP has strengthened our balance sheet and enables us to increase our ownership in Biocon Biologics.”

Biosimilars revenue, which constitutes 61% of revenues, rose 18% YoY to Rs 2,458 crore, with EBITDA up 36% to Rs 645 crore and margins stood at 26% on like-to-like basis.

The company launched Yesafili in Canada and received USFDA approval for Kirsty, its second interchangeable biosimilar insulin.

Generics revenue grew 6% YoY to Rs 697 crore, driven by new launches including Liraglutide in the EU and Dasatinib in the US.

CRDMO (Syngene) revenue rose 11% YoY to Rs 875 crore, with EBITDA up 19% to Rs 224 crore, supported by long-term contract conversions and expanded scientific capabilities.

Biocon raised Rs 4,500 crore via a Qualified Institutions Placement (QIP) in June to consolidate its stake in Biocon Biologics and facilitate investor exits. The company also commissioned a new GLP-1-focused injectable facility in Bangalore, with commercialization expected in FY27.

With 19 global launches and 12 biosimilars already commercialized, Biocon is expanding its footprint in advanced and emerging markets. “We are confident in our ability to scale, deepen market presence, and deliver sustained growth,” said Shreehas Tambe, CEO of Biocon Biologics.